Special Issue "Stereotactic Body Radiotherapy"
Deadline for manuscript submissions: 10 September 2021.
Interests: Conformal Radiation Therapy; Stereotactic Radiotherapy; Ablative Radiotherapy; Intensity Modulated Radiation Therapy; Radiobiology; Breast Cancer; Urological Tumours; Prostate Cancer
Special Issues and Collections in MDPI journals
Stereotactic radiotherapy (SRT) is a treatment option curing cancer that creates highly conformal dose distributions with steep dose gradients, using advanced planning and treatment equipment. Stereotactic radiotherapy allows for the safe delivery of high doses of radiation to the target lesion, while sparing the surrounding critical organs. More specifically, in clinical practice, it is a useful tool in patients affected by limited metastatic disease, defined as an “oligometastatic state”, which is considered as an intermediate state between localized and widespread cancer. In patients with a limited number of metastases from a variety of primary sites, it seems that SRT might improve overall survival and disease-progression-free survival, with a limited cost in terms of treatment-related morbidity. SRT is also under investigation for the treatment of primary tumors, instead of surgery or conventional radiotherapy, such as for curing lung cancer and prostate cancer. For these reasons, this Special Issue will explore the use of stereotactic radiotherapy in the therapy of solid tumors. Researchers are encouraged to submit their scientific contributions for “Stereotactic Body Radiotherapy”.
Dr. Gianluca Ingrosso
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Stereotactic radiotherapy
- Solid tumors
- Stereotactic body radiotherapy
- Stereotactic ablative body radiotherapy